James G. Groninger

Mr. Groninger is CEO of LBS Technologies, Inc., a private biotechnology company focusing on RNA amplification and cellular therapy, and the lead investor in Expression Pathology, Inc.’s Series A Preferred offering. Mr. Groninger founded and is President of The Bay South Company, a Richmond, Virginia-based provider of financial advisory and investment banking services. From 1988 through 1994, he served as a Managing Director, Investment Banking Division, of PaineWebber Inc., now UBS. Mr. Groninger is a member of the board of directors of NPS Pharmaceuticals, Inc. and Cygne Designs, Inc., both publicly held companies, and LBS Technologies. Mr. Groninger received an M.B.A. degree from Harvard Business School and a B.S. from Yale University. He is a CPA and a CFA.